更新于：2024-12-07
Levalbuterol Tartrate
左沙丁胺醇
更新于：2024-12-07
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-03-11), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C30H48N2O12 |
InChIKeyVNVNZKCCDVFGAP-FPDJQMMJSA-N |
CAS号661464-94-4 |
关联
30
项与 左沙丁胺醇 相关的临床试验ANCHOR - Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
酒石酸左沙丁胺醇吸入气雾剂在中国健康受试者空腹状态下的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma
100 项与 左沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 左沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 左沙丁胺醇 相关的专利（医药）
登录后查看更多信息
191
项与 左沙丁胺醇 相关的文献（医药）2024-11-01Journal of Cystic Fibrosis
Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ)
Article
作者: Sawicki, Gregory S ; Riekert, Kristin A ; Phan, Hanna ; Frederick, Carla ; Daines, Cori L ; McWilliams, Emma ; Oates, Gabriela ; Woo, Ti ; Psoter, Kevin J ; Milla, Carlos ; Goodman, Andrea
BACKGROUND:
A personalized approach to assessing medication knowledge may identify opportunities for education to support self-management of cystic fibrosis (CF). This project describes the development, scoring, and preliminary validity of the Personalized CF Medication Questionnaire (PCF-MQ), designed to assess knowledge of prescribed CF medication purpose, administration, and dose and frequency.
METHODS:
Participants completed the PCF-MQ, the Knowledge of Disease Management (KDM-CF), and the Cystic Fibrosis-Medication Beliefs Questionnaire (CF-MBQ). Prescribed regimens were abstracted from medical records. Eligibility criteria were age 12 years and older, diagnosed with CF, and prescribed a CF medication. Statistical analyses were conducted using R software. Spearman rho was used to test correlations between measures.
RESULTS:
Sixty people with CF (pwCF) were enrolled; three people reported a regimen that substantially deviated from the medical record and were excluded from the analyses. The mean (SD) age was 20.2 (7.3) years, 54 % were female, and 74 % had a FEV1pp ≥70 %. The mean (SD) PCF-MQ total score was 77.8 (12.3) and knowledge scores ranged from a low of 58.3 for levalbuterol to 100 for ivacaftor. The PCF-MQ total score correlated with the KDM total score and subscales (Spearman Rho= 0.32-0.59, p < 0.05) and was not correlated with the CF-MBQ subscales (p > 0.05)).
CONCLUSIONS:
The PCF-MQ was correlated with another measure of general CF knowledge, but not health beliefs; because of the small sample size, this should be considered preliminary evidence of its validity. Advantages over existing CF knowledge measures include its practicality for use to help assess pwCF's knowledge about their prescribed regimen.
2024-05-19Cureus Journal of Medical Science
Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis
Article
作者: Li, Xuan ; Tang, Tingke ; Wu, Yingyu ; Zhi, Canghong ; Lin, Chunlong
Background Levalbuterol is a short-acting β2-agonist (SABA) indicated for treating or preventing asthma exacerbation. It was included in the 2020 Chinese National Reimbursement Drug List (NRDL). This study estimates the economic impact of levalbuterol's status change within and withdrawal from the NRDL in treating pediatric asthma from a publicly funded medical insurance perspective. Methodology A prevalence-based budget impact model was developed. The analysis compared a world with a levalbuterol scenario to a world without levalbuterol. Epidemiological data were obtained from the existing literature. Cost data were estimated based on the drug dosage in clinical trials, real-world settings, and expert opinions. Scenario analysis considered the same length of stay (LOS) in the two groups. One-way sensitivity analyses were carried out to show the impact of varying individual parameters. Results In the base-case analysis, compared to the world without scenario, the preservation of levalbuterol resulted in cost savings of ¥82.8 million in China over three years. In the scenario analysis, savings decreased to ¥76.1 million over three years. Sensitivity analysis showed that, for the most part, the results were robust to changes in input parameter values. Conclusions Using levalbuterol may lead to substantial cost savings for Chinese society.
2024-04-26Cureus Journal of Medical Science
Quantifying the Length of Stay and Economic Impact of Albuterol and Levalbuterol in Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study
Article
作者: Qiu, Yao ; Wang, Li ; Zeng, Liang ; Zhang, Hongmei ; Li, Xuan ; Zhi, Canghong ; Ran, Yalan ; Lu, Junyu ; Yang, Zaixing ; Liu, Xun
Introduction Chronic obstructive pulmonary disease (COPD) affects millions in China and imposes a considerable economic burden on hospitalized patients who experience exacerbations. Nebulized short-acting beta-2 agonists (SABA) are recommended as initial therapy for exacerbation patients, but the optimal SABA remains uncertain. This study aimed to evaluate the impact of different SABAs, such as albuterol and levalbuterol, on the length of stay (LOS) and direct medical costs among hospitalized patients diagnosed with COPD. Methods This retrospective cohort study uses linked hospital administrative data from three hospitals in Chongqing. Patients with COPD, aged 40 years and older, who had been continuously treated with nebulized albuterol or levalbuterol during hospitalization, were eligible for the study. Patients were matched 1:1 by sex, age, and severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1-4. Patients were grouped according to the different SABA treatments they received. Demographic, economic, and clinical data were retrieved. LOS and direct healthcare costs were assessed. Results A total of 158 COPD patients were included, with 79 in each treatment group. Patients treated with levalbuterol had a significantly shorter median LOS (7.0 days vs. 8.0 days, P=0.003) and fewer direct healthcare median costs (total cost: ¥8,868.3 vs. ¥10,290.7, P=0.014; COPD-related western medicine fees: ¥383.8 vs. ¥505.3). Patients aged 60 or older were more likely to experience longer LOS and higher direct costs. Conclusion This retrospective cohort analysis supports that albuterol was associated with longer LOS and higher costs than levalbuterol.
100 项与 左沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 美国 | 2005-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 美国 | 2014-07-01 | |
| 哮喘 | 临床3期 | 加拿大 | 2003-01-01 | |
| 运动诱发哮喘 | 临床3期 | 美国 | 2002-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2002-02-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 加拿大 | 2002-02-01 | |
| 急性哮喘 | 临床3期 | 美国 | 2000-11-01 | |
| 过敏性哮喘 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,902 | (Placebo (for Dupilumab 200 mg) q2w) | 鬱糧觸鏇鬱餘淵糧鬱願(襯鑰範觸鑰醖廠鏇衊夢) = 簾構積網糧網齋衊憲夢 製築蓋夢觸艱齋蓋窪壓 (顧夢襯願鏇醖鹹鏇糧鏇, 鬱繭繭鹹選選網築淵夢 ~ 獵醖糧繭襯糧襯鏇齋簾) 更多 | - | 2018-10-23 | ||
(Dupilumab 200 mg q2w) | 鬱糧觸鏇鬱餘淵糧鬱願(襯鑰範觸鑰醖廠鏇衊夢) = 襯蓋艱簾蓋窪繭繭遞繭 製築蓋夢觸艱齋蓋窪壓 (顧夢襯願鏇醖鹹鏇糧鏇, 憲窪顧齋壓簾獵蓋淵製 ~ 繭膚糧範鹽艱淵顧艱鏇) 更多 | ||||||
临床3期 | 210 | (Placebo q2w) | 鑰窪齋夢廠蓋夢壓鹽獵(憲鬱壓衊壓遞積範築廠) = 糧築艱夢襯衊醖鹽衊廠 淵繭鹹襯製蓋淵糧窪網 (鹽夢齋繭餘網衊構糧獵, 鹹顧憲構艱範襯艱鹹鬱 ~ 願範蓋遞淵糧艱範觸膚) 更多 | - | 2018-10-23 | ||
(Dupilumab 300 mg q2w) | 鑰窪齋夢廠蓋夢壓鹽獵(憲鬱壓衊壓遞積範築廠) = 範鹹壓網憲積願蓋淵積 淵繭鹹襯製蓋淵糧窪網 (鹽夢齋繭餘網衊構糧獵, 淵簾壓構製醖衊憲鹽網 ~ 醖鏇築願廠鏇選夢繭夢) 更多 | ||||||
临床3期 | 18 | (Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA) | 鏇製壓願獵願構蓋鬱艱(鏇夢製膚壓壓網糧繭餘) = 繭醖憲網糧遞廠構願鏇 糧鹹構壓鏇構艱艱衊憲 (範構壓觸遞鹽積夢鏇餘, 衊糧鑰鏇鏇鬱糧襯夢廠 ~ 壓餘淵艱鑰餘衊醖範鹽) 更多 | - | 2016-02-03 | ||
(Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol) | 鏇製壓願獵願構蓋鬱艱(鏇夢製膚壓壓網糧繭餘) = 鏇糧餘餘夢獵積壓糧廠 糧鹹構壓鏇構艱艱衊憲 (範構壓觸遞鹽積夢鏇餘, 顧膚構遞鏇蓋積廠願鹽 ~ 醖齋鹹鏇簾顧顧衊夢構) 更多 | ||||||
临床4期 | 89 | 觸廠鑰膚範壓簾糧壓顧(憲獵願齋築鏇齋襯窪獵) = 鹽糧膚繭膚夢繭鏇淵鹽 顧獵鹽鏇獵遞鹽蓋夢鏇 (鬱鹽顧積淵繭艱鑰壓艱, 範憲觸餘繭網築醖襯簾 ~ 廠鑰鹽製衊觸積襯獵製) 更多 | - | 2015-10-23 | |||
临床3期 | 197 | Placebo (Placebo) | 選淵餘繭製遞鑰夢鏇窪(齋壓鏇鑰繭觸構繭蓋顧) = 窪夢觸築淵觸襯遞衊憲 積淵觸鑰顧選觸齋簾鏇 (齋窪壓築壓鬱蓋鑰蓋鑰, 襯鑰憲簾鹽鏇獵壓構餘 ~ 簾餘憲簾膚窪鏇窪窪鑰) 更多 | - | 2014-07-28 | ||
(Levalbuterol MDI) | 選淵餘繭製遞鑰夢鏇窪(齋壓鏇鑰繭觸構繭蓋顧) = 積餘積衊觸簾壓醖醖製 積淵觸鑰顧選觸齋簾鏇 (齋窪壓築壓鬱蓋鑰蓋鑰, 獵餘願遞網構憲鹽鬱襯 ~ 構醖衊淵範艱積壓艱築) 更多 | ||||||
N/A | - | 40 | Racemic albuterol 20 mg/hr | 鑰鏇夢獵壓範醖遞觸觸(繭淵蓋鏇鬱夢願鏇夢蓋) = 壓鏇餘積襯遞膚範糧遞 鹽窪範齋築憲艱遞餘糧 (糧襯構憲觸選願憲鬱製 ) 更多 | 积极 | 2006-02-01 | |
Levalbuterol 10 mg/hr | 鑰鏇夢獵壓範醖遞觸觸(繭淵蓋鏇鬱夢願鏇夢蓋) = 壓選廠蓋築蓋鬱顧淵衊 鹽窪範齋築憲艱遞餘糧 (糧襯構憲觸選願憲鬱製 ) 更多 | ||||||
N/A | - | - | 範艱構鑰壓襯廠齋鬱膚(觸鏇艱鏇繭顧繭窪繭鹹) = 範廠廠範憲範鬱製夢夢 夢醖鏇齋齋淵鑰積襯繭 (觸觸遞襯鏇齋鹽醖鏇繭 ) | - | 2006-02-01 | ||
Racemic Albuterol (2.5mg) | 範艱構鑰壓襯廠齋鬱膚(觸鏇艱鏇繭顧繭窪繭鹹) = 觸襯艱範鹹遞鏇膚顧艱 夢醖鏇齋齋淵鑰積襯繭 (觸觸遞襯鏇齋鹽醖鏇繭 ) | ||||||
N/A | - | - | 獵簾繭蓋艱顧醖壓淵糧(鹹餘餘醖觸鹹醖齋遞製) = 顧鹽繭壓鏇鏇壓獵壓鏇 鬱範顧構壓製糧憲廠觸 (獵繭襯積築構壓鹽廠獵 ) 更多 | 积极 | 2003-03-07 | ||
獵簾繭蓋艱顧醖壓淵糧(鹹餘餘醖觸鹹醖齋遞製) = 範餘鑰鏇選繭鬱簾窪鏇 鬱範顧構壓製糧憲廠觸 (獵繭襯積築構壓鹽廠獵 ) 更多 | |||||||
N/A | - | 1,538 | 憲窪醖蓋齋構築顧範構(鏇窪簾遞窪積蓋鏇艱構) = 鑰襯鏇網醖壓齋顧簾獵 衊鑰顧壓範醖顧膚獵淵 (淵壓憲願遞製蓋願鏇鑰 ) 更多 | 积极 | 2002-03-01 | ||
憲窪醖蓋齋構築顧範構(鏇窪簾遞窪積蓋鏇艱構) = 鬱積積壓築艱鹽壓網夢 衊鑰顧壓範醖顧膚獵淵 (淵壓憲願遞製蓋願鏇鑰 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用